Stacey Johnson
Stacey Johnson is the editor of Signals and a contributor. For 25 years, Stacey has been providing strategic communications counsel to government, corporate, technology and health organizations. She began her career at the CTV Television Network and then moved to Hill & Knowlton Canada where she advised clients in a variety of industries and sectors. Stacey is the Vice President, Communications and Marketing for CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies. She has a Master's degree in Public Relations. You can follow her on Twitter @msstaceyerin.
Posts by: Stacey
Right Turn: Did you miss last year’s blog carnival? Don’t worry it’s back!
It’s August already. For many, this means vacation time and soaking up as much summer as possible before work and life ramp up again in the fall. For me, August means multiple family birthdays ($) and the return of the blog carnival! What is a blog carnival you ask? Signals launched its first blog carnival […]
Right Turn: Promising model for rare diseases in Bespoke Gene Therapy Consortium
The definition of a rare disease in the U.S. is under 200,000 patients. The 10 per cent of Americans living with a rare disease is equivalent to 30 million people. Put another way, that is close to the entire population of Canada (at 39 million). There are 7,000 – 10,000 rare diseases in the U.S. […]
Right Turn: Surviving the cure
Courtney Horvath, PhD, is a board certified toxicologist who knows firsthand about toxicity in pediatric oncology treatments. Her son, Colby, was diagnosed with lymphoma at the age of eight, in March 2020, and she has since become an advocate for better cancer treatments for children. At the end of this post I have shared a […]
Blog carnival: Challenges and proposed solutions to support a deluge of new CGT approvals
It’s exciting news that there are close to 2,000 advanced therapies currently in clinical trials around the world. But is it good news? It’s exciting to see how far the cell and gene therapy (CGT) industry has come and how quickly the pipeline is growing. It’s exciting that this potentially represents new treatments for patients […]